The financing round for Isomorphic, who specializes in developing drugs through artificial intelligence, was led by investors Greenoaks and Sequioa Capital.
Isomorphic Labs Drug Design Engine (IsoDDE) is a system to simulate different AI models, with the ambition of developing drugs to multiple therapeutic areas. The AI models are combined with the company's researchers to optimise the AI-development into potential candidates.